Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(5):331-333; doi:10.1093/jnci/97.5.331
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Related Collections
Right arrowRelated News Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Trial and Error: Prognostic Gene Signature Study Design Altered

Rabiya S. Tuma

The first 10% of the full text of this article appears below.

The first prospective randomized trial to test the efficacy of a prognostic microarray gene signature is scheduled to begin enrollment in September. However, in a meeting held at the St. Gallen conference in Switzerland in late January, the steering committee decided to substantially alter the trial's design. The changes are reflective of a field in flux, a situation highlighted by several new approaches designed to improve the value of molecular array data in cancer prognosis.

The trial in question, Microarray for Node-Negative Disease may Avoid Chemotherapy (MINDACT), was originally designed to compare the ability of a 70-gene prognostic profile versus clinical and pathological criteria to identify women with node-negative breast cancer who are unlikely to benefit from adjuvant chemotherapy. The hypothesis was that by using the 70-gene prognostic profile, . . . [Full Text of this Article]

Validating the Signature


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related News Article in JNCI

Multiple Gene Signatures Aim to Qualify Risk in Breast Cancer
Rabiya S. Tuma
J Natl Cancer Inst 2005 97: 332. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
D. H. Roukos, E. Paraskevaidis, and A. M. Kappas
Surgery in the Era of Gene Expression Profiling-Based Prediction and Individualized, Neoadjuvant Breast Cancer Therapy: The Beginning of the End?
Ann. Surg. Oncol., March 1, 2006; 13(3): 433 - 435.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J S Reis-Filho, C Westbury, and J-Y Pierga
The impact of expression profiling on prognostic and predictive testing in breast cancer.
J. Clin. Pathol., March 1, 2006; 59(3): 225 - 231.
[Abstract] [Full Text] [PDF]